Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.91 |
| ▸ | FAAH | O00519 | 1/20 | 0.91 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.91 |
| ▸ | CNR2 | P34972 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linoleoylethanolamide SCHEMBL653623 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL30306296 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL6259736 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL14106445 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL14864036 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| Linoleoylethanolamide SCHEMBL5145794 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL5412597 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL14106447 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| Linoleoylethanolamide SCHEMBL13110450 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL1334847 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1HPGDTRPV1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | INMED PHARMACEUTICALS INC (CA) | 2020-09-17 | — | — | US | claimed |
| EP-3684353-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | Inmed Pharmaceuticals Inc. (CA) | 2020-07-29 | — | — | EP | claimed |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2019-05-16 | — | — | US | claimed |
| WO-2019056123-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | INMED PHARMACEUTICALS INC. (CA) | 2019-03-28 | — | — | WO | claimed |
| EP-3452036-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | Inmed Pharmaceuticals Inc. (CA) | 2019-03-13 | — | — | EP | claimed |
| WO-2017190249-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2017-11-09 | — | — | WO | claimed |
| US-12042479-B2 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | INMED PHARMACEUTICALS INC. | 2024-07-23 | — | — | US | disclosed |
| US-20240082270-A1 | CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USE | BAZELET HEALTH SYSTEMS INC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024044776-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023102541-A1 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220170056-A1 | COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM | INMED PHARMACEUTICALS INC. (CA) | 2022-06-02 | — | — | US | disclosed |
| EP-3935178-A1 | COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM | Inmed Pharmaceuticals Inc. (CA) | 2022-01-12 | — | — | EP | disclosed |
| US-11129842-B2 | Methods and compositions for treating diseases related to imbalance of essential fatty acids | BODYBIO INC (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2017190249-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319607-A1 | METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS OF DISEASES RELATED TO IMBALANCE OF ESSENTIAL FATTY ACIDS | BODYBIO INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9655910-B2 | Compositions and methods for treating addiction | BODYBIO INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150265636-A1 | COMPOSITIONS AND METHODS FOR TREATING ADDICTION | BODYBIO INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150265637-A1 | METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS OF DISEASES RELATED TO IMBALANCE OF ESSENTIAL FATTY ACIDS | BODYBIO INC. (US) | 2015-09-24 | — | — | US | disclosed |
| WO-2015142501-A1 | METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS OF DISEASES RELATED TO IMBALANCE OF ESSENTIAL FATTY ACIDS | BODYBIO INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015142500-A2 | COMPOSITIONS AND METHODS FOR TREATING ADDICTION | BODYBIO INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | CNR2, CNR1, LCAT | CNR1 2/4885ALDH1A1 4229/4885HPGD 947/4885 |
| US-12042479-B2 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | KRT18, DSP, DSC1 | CNR1 60/4885ALDH1A1 4687/4885HPGD 2473/4885 |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | KRT18, DSP, DSC1 | CNR1 60/4885ALDH1A1 4687/4885HPGD 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.